Dried Blood Spot (DBS) as a useful tool to improve clozapine, aripiprazole and paliperidone treatment: From adherence to efficiency.

[1]  E. Fernandez-Egea.  Waiting for Godot or the use of biomarkers in clinical practice. , 2021, Revista de psiquiatria y salud mental.

[2]  T. van Gelder,et al.  Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Antipsychotics: Drawbacks of Its Clinical Application , 2018, Therapeutic drug monitoring.

[3]  M. Broder,et al.  Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder , 2018, Journal of medical economics.

[4]  P. Ljungdalh.  Non-adherence to pharmacological treatment in schizophrenia and schizophrenia spectrum disorders – An updated systematic literature review , 2017 .

[5]  E. Spina,et al.  A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone , 2017, Expert review of clinical pharmacology.

[6]  T. van Gelder,et al.  Dried Blood Spots Combined With Ultra–High-Performance Liquid Chromatography–Mass Spectrometry for the Quantification of the Antipsychotics Risperidone, Aripiprazole, Pipamperone, and Their Major Metabolites , 2017, Therapeutic drug monitoring.

[7]  A. Schene,et al.  Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring , 2017, European Neuropsychopharmacology.

[8]  J. Castro-Fornieles,et al.  Modelling gene-environment interaction in first episodes of psychosis , 2017, Schizophrenia Research.

[9]  C. E. Bright.  Measuring Medication Adherence in Patients With Schizophrenia: An Integrative Review , 2017, Archives of psychiatric nursing.

[10]  John M. Davis,et al.  Dose Equivalents for Antipsychotic Drugs: The DDD Method. , 2016, Schizophrenia bulletin.

[11]  H. Neels,et al.  Are capillary DBS applicable for therapeutic drug monitoring of common antipsychotics? A proof of concept. , 2015, Bioanalysis.

[12]  A. David,et al.  Antipsychotic therapeutic drug monitoring: psychiatrists’ attitudes and factors predicting likely future use , 2015, Therapeutic advances in psychopharmacology.

[13]  H. Neels,et al.  The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography - tandem mass spectrometry. , 2015, Drug testing and analysis.

[14]  H. Neels,et al.  Advances in detection of antipsychotics in biological matrices. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[15]  M. Grundmann,et al.  Therapeutic drug monitoring of atypical antipsychotic drugs , 2014, Acta pharmaceutica.

[16]  Bernard Sabbe,et al.  High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[17]  M. De Hert,et al.  Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review , 2013, Therapeutic advances in psychopharmacology.

[18]  D. Fisher,et al.  LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood. , 2013, Forensic science international.

[19]  S. Seedat,et al.  Plasma, Oral Fluid, and Whole-Blood Distribution of Antipsychotics and Metabolites in Clinical Samples , 2013, Therapeutic drug monitoring.

[20]  H. Mcdonald,et al.  Interventions to enhance patient adherence to medication prescriptions: scientific review. , 2002, JAMA.

[21]  L. Green,et al.  Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.

[22]  T. Hogan,et al.  A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity , 1983, Psychological Medicine.